Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy

Journal of Urology

Volumn 182, Issue 2, 2009, Pages 491-498

  Bañez, Lionel L ^a,b   Sun, Leon ^a   Trock, Bruce J ^c   Han, Misop ^c   Partin, Alan W ^c   Aronson, William J ^d   Terris, Martha K ^g   Presti Jr , Joseph C ^e   Kane, Christopher J ^f   Amling, Christopher L ^h   Moul, Judd W ^a   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

hemodilution; obesity; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; ARTICLE; BODY MASS; CANCER INVASION; CHEMICAL ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; GLEASON SCORE; HEMODILUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEMINAL VESICLE; VETERAN;

BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67649819338     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.04.007     Document Type: Article

References (27)

1. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110
2. Freedland S.J., Grubb K.A., Yiu S.K., et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 174 (2005) 919
3. Ulmert D., Serio A.M., O'Brien M.F., et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26 (2008) 835
4. Connolly D., Black A., Gavin A., et al. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 17 (2008) 271
5. Amling C.L., Kane C.J., Riffenburgh R.H., et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58 (2001) 723
6. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446
7. Rodriguez C., Freedland S.J., Deka A., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16 (2007) 63
8. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348 (2003) 1625
9. Baillargeon J., Pollock B.H., Kristal A.R., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103 (2005) 1092
10. Barqawi A.B., Golden B.K., O'Donnell C., et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65 (2005) 708
11. Gray M.A., Delahunt B., Fowles J.R., et al. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 24 (2004) 2069
12. Ku J.H., Kim M.E., Lee N.K., et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61 (2003) 132
13. Werny D.M., Thompson T., Saraiya M., et al. Obesity is negatively associated with prostate-specific antigen in U. S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16 (2007) 70
14. Fowke J.H., Motley S.S., Cookson M.S., et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10 (2007) 137
15. Bañez L.L., Hamilton R.J., Partin A.W., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (2007) 2275
16. Price M.M., Hamilton R.J., Robertson C.N., et al. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 71 (2008) 787
17. Rundle A., and Neugut A.I. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68 (2008) 373
18. Ando R., Nagaya T., Hashimoto Y., et al. Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004-2006. Urology 72 (2008) 561
19. Harrell Jr. F.E., Califf R.M., Pryor D.B., et al. Evaluating the yield of medical tests. JAMA 247 (1982) 2543
20. Department of Health and Human Services Centers for Disease Control and Prevention. Overweight and Obesity: U. S. Obesity Trends 1985-2007, vol 2008. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm Accessed November 22, 2008.
21. Freedland S.J., Terris M.K., Platz E.A., et al. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 66 (2005) 108
22. Freedland S.J., Isaacs W.B., Mangold L.A., et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 11 (2005) 2883
23. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
24. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
25. Schroeck F.R., Sun L., Freedland S.J., et al. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 11 (2008) 371
26. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128
27. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176 (2006) 1404